Project Grant R01DA061773
Award Date
9/15/24
Completion Date
5/31/29
Dollars Obligated
$2.1M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
This $265,302 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the neural mechanisms underlying opioid use disorder (OUD) and relapse risk during abstinence. The funded project will map the functional and anatomical pathways between the anterior and posterior paraventricular nucleus of the thalamus (PVT) and the nucleus accumbens (NAc), which have been implicated in the...
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $267,310 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Regents of the University of Minnesota. The award will fund research to investigate the role of the neuropeptide VGF and its derived peptide TLQP-62 in facilitating synaptic plasticity in the nucleus accumbens and their contribution to opioid withdrawal behaviors. Key research activities include...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $818,513.00 to investigate the role of dopamine signaling in the basolateral amygdala on individual differences in reward-learning strategies and addiction-like behaviors. The 5-year study, starting on September 15, 2024, will focus on how Pavlovian reward-learning strategies, such as sign tracking versus goal tracking, predict unique...
This Project Grant award of $847,000 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to evaluate the therapeutic potential of the neuropeptide S receptor 1 (NPSR1) as a target for reducing opioid self-administration and relapse in opioid use disorder (OUD). The research team at the University of Tennessee Health Science Center plans to leverage pharmacological tools to agonize and antagonize NPSR1 and test...
This Project Grant award of $239,963 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to investigate the functional consequences of the interactions between the tau protein and opioids. The project aims to test the hypothesis that opioid use, particularly of the opioid oxycodone, leads to enhanced tau phosphorylation and oligomerization in the prefrontal cortex, which may in turn cause synaptic dysfunction and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), supports research to identify and validate G protein-coupled receptors (GPCRs) expressed by somatostatin-expressing inhibitory neurons in the prefrontal cortex as potential targets for developing new treatments for opioid use disorder. The $1,717,200 award, spanning August 1, 2024 to May 31, 2029, will enable researchers at the University of...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $419,876 to conduct preclinical trials targeting the neuropeptide S (NPS) receptor to mitigate opioid taking and seeking behaviors in animal models. The goals of the project are to demonstrate proof-of-concept that NPS receptor-targeted molecules can reduce oxycodone self-administration and motivation in rats, which could inform the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the role of cholinergic interneurons in the ventral tegmental area on opioid-related behaviors. The $373,181 grant, awarded on July 15, 2024 with a completion date of June 30, 2027, aims to determine whether mu-opioid receptors on cholinergic interneurons contribute to opioid reward, consumption, and withdrawal, and how...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $232,128 to the Regents of the University of Minnesota to characterize the role of dopaminergic and glutamatergic mechanisms in the basolateral amygdala (BLA) that underlie dynamic drug-seeking behaviors. The research aims to measure in vivo dopamine signaling and D1-neuron activity in the BLA during cocaine self-administration, as well...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $358,012 to the Regents of the University of Minnesota to investigate input-specific synaptic plasticity in the nucleus accumbens evoked by inhibition of angiotensin-converting enzyme. The goal is to determine which specific excitatory and inhibitory presynaptic inputs to medium spiny neurons in the nucleus accumbens express this form of...